The 2010 National Institutes of Health (NIH) Asthma Outcomes Workshop (AOW) reviewed existing instruments and procedures for measurement of all types of asthma outcome measures. With respect to asthma-related quality of life (QoL), 1 the AOW concluded that assessing the disease effect on patients' QoL remains an essential component of the asthma outcome measurement toolbox. 2 However, it also concluded that no available asthma-specific QoL measures, even those in widespread use, actually assess a patient's perception of the effect of asthma on his or her QoL. 2 Instead, existing instruments measure the patient's status in physical, mental, and social health domains as these relate to asthma. The conceptual frameworks of such measures consist of health domains, symptom frequency and severity, how much asthma limits the subject's activities (ie, their functional status), and in some cases negative emotions related to asthma, such as concerns, fears, or embarrassment.
The AOW recognized that the content validity of a measure is fundamental, which means that, except in rare instances, the content of a measure should have a very direct and obvious relationship to its intended purpose and the construct it purports to measure. 3 The fact that a health status measure is reliable is logically correlated with other measures of asthma status, and the fact that it contains items about the frequency and intensity of functional limitations does not mean it is a valid measure of the patient's perception of how or how much asthma affects their QoL, a judgment that can only be made by the patient. The effects of asthma on QoL are very likely to be determined by factors in addition to symptoms and functional limitations, such as how important it is to the patient to engage in particular activities and how difficult it is for them to avoid things that trigger their asthma without having to forego valued activities. Existing instruments might provide an assessment of a subject's asthma and functional status. However, the fact that they do not assess a patient's perception of how the disease affects his or her QoL is what led the AOW not to recommend any existing instrument as a core QoL measure for use in asthma clinical research.
In the 1970s, by gathering and analyzing narrative reports from a large and diverse sample of adults across the United States regarding events/experiences that significantly affected their own QoL (positively or negatively), eminent psychologist John C. Flanagan identified 15 dimensions that affect individuals' QoL (Fig 1) . 4 He then developed the Flanagan Quality of Life Scale (QOLS), on which individuals can rate the extent to which their needs and wants are being met on each dimension. 5 In essence, Flanagan considered the QoL of a person as defined by how well that person believed that his or her needs and wants were being satisfied across all the dimensions of life. The QOLS, a generic measure that can be used with any adult, regardless of health status, does not ask the person completing the questionnaire to assess the contribution of any particular factor to their QoL.
We propose an approach to measuring a person's perception of the effect of a disease on their QoL that uses Flanagan's QoL dimensions and one dimension suggested by Burckhardt. 6 As an initial example of this approach, we created the Asthma Impact on Quality of Life Scale (A-IQOLS). Rather than asking how well the subject's needs and wants are being satisfied, the A-IQOLS asks the subjects to rate the negative effect of a disease and its treatment on each QoL dimension. Here we report the A-IQOLS' development process and the methods and results of a test-retest study to determine its psychometric properties in patients with persistent asthma.
An alternative to the A-IQOLS approach would be to simply measure patients' perception of their QoL (eg, by using the QOLS) and then infer the effect of their disease based on temporal changes or between-group differences in QOLS scores. Both the A-IQOLS and QOLS were administered in this study to compare these alternatives in asthmatic patients and because both types of instruments could have potential uses in research and clinical practice. To assess the current relevance of the QoL dimensions, we also obtained patients' ratings of the personal importance of each dimension.
METHODS
The research reported here was supported by grant number HL119845 (principal investigator S.R.W.) from the National Heart, Lung, and Blood Institute/NIH. The study is approved by the Sutter Health institutional review board (SHIRB no. 14-06-327).
Instrument development and pilot testing
The development of the A-IQOLS and the pilot testing of the A-IQOLS, Flanagan's Importance questionnaire, and his QOLS in asthmatic patients are described in the Methods section in this article's Online Repository at www. jacionline.org. These measurement instruments, as used in the present study, are presented in Fig E1 in this article' s Online Repository at www. jacionline.org, followed by their administration instructions. The history of the development and use of the QOLS by Flanagan also is described in the Methods section in this article's Online Repository, as are subsequent modifications made by other investigators. Key distinctions between these versions are described to clarify the rationale for using the stem question and rating scale of Flanagan's preferred QOLS in the present study.
Test-retest study sample Eligibility: inclusion criteria. 
Recruitment
Patients potentially meeting the inclusion criteria were identified by querying electronic clinical and administrative records and randomly selected for recruitment by using a disproportionate stratified sampling methodology with stratification by race, ethnicity, sex, and treatment step of the patient's current asthma controller regimen. 7 Sampling probabilities were designed to achieve a distribution that (1) corresponded to the sex and race distribution in the US asthmatic population and (2) ensured a more uniform distribution across asthma treatment steps (and, by inference, levels of asthma severity) than would have resulted from randomly sampling patients with persistent asthma, most of whom would have had mild or moderate disease. Potential participants were contacted by telephone, screened, and (if eligible and interested) scheduled for an initial clinic visit.
Patient assessment
At baseline, informed consent and anthropometric measurements were obtained, prebronchodilator and postbronchodilator spirometry were performed before and after a bronchodilator, and a questionnaire was selfadministered. Prebronchodilator spirometry and the questionnaire were repeated 4 weeks later (3-5 weeks depending on patients' availability).
Importance of QoL dimensions. This measure asks respondents to rate how important each of the dimensions is to them on a scale from 1 (ie, not at all important) to 5 (ie, very important). Repository at www.jacionline.org) asks patients to rate how well their needs and wants are being satisfied on each QoL dimension by using a bidirectional scale from 1 (ie, not at all well satisfied) to 5 (ie, very well satisfied). 6 A-IQOLS. The A-IQOLS (see Fig E1) asks respondents to rate the negative effect of their asthma and its treatment over the preceding 4 weeks on each of 16 QoL dimensions by using a standard unidirectional scale ranging from 1 (ie, no negative effect at all) to 5 (ie, extremely negative effect).
Other standardized asthma outcome measures.
Asthma control, symptoms, and functional impairment were assessed by using the Asthma Control Test (ACT), 8 Asthma Symptom Utility Index (ASUI), 9 Marks Asthma Quality of Life Questionnaire (Marks AQLQ), 10 and Juniper Mini Asthma Quality of Life Questionnaire, 11 all widely used in asthma research. The Patient Health Questionnaire (PHQ-9) 12 was used to assess depression.
Spirometry. Research coordinators, certified for occupational spirometry by the National Institute of Occupational Safety and Health, used standardized research methods and equipment that met or exceeded American Thoracic Society standards. 13 Percent predicted prebronchodilator FEV 1 based on age-, sex-and race-specific norms 14 is considered a core physiologic measure in asthma research. 15 
Statistical analysis
Descriptive statistics were computed for patients' demographic and clinical characteristics. The A-IQOLS and QOLS summary scores were the averages of their respective dimension ratings. Other standardized asthma outcome measures were scored and scaled by using their published algorithms. 8, 11, [16] [17] [18] [19] [20] Differences between the test and retest administrations on all measures were evaluated by using t tests (continuous variables) and x 2 tests (categorical variables). Associations between pairs of measures were assessed by using Spearman or Pearson rank-order correlation coefficients, as appropriate to their distributional properties. The importance questionnaire has no summary score; dimension importance ratings are considered individually.
Measurement reliability. Asthma being an inherently variable disease, it is not reasonable to assume that all changes that might be observed over a 3-to 5-week period are entirely due to errors of measurement and not to real changes in the underlying construct a given measure is designed to assess. However, the baseline and associated follow-up assessments were fairly uniformly distributed over all seasons of the year, and the 3-to 5-week testretest interval, although arguably long enough to reduce recall influences, was short enough to minimize systematic seasonal changes in asthma status. It is expected that the observed variability in disease status would be typical of the variability that would occur in a clinical trial at a similar interval in the absence of any specific intervention.
By using repeated assessments of each patient, a 2-way repeated-measures ANOVAwas used to calculate (1) the intraclass correlation coefficient (ICC), a relative reliability index, and (2) the within-subject variance, the square root of which is the estimated standard error of measurement (SEM), a less population-dependent reliability index that, unlike the ICC, can be interpreted on the original response scale. The repeatability coefficient is based on the SEM (coefficient of repeatability [CR] 5 2.77 3 SEM) 21 and is the smallest within-person change that can be considered, with 95% confidence, to be a real change. The upper and lower bounds of the 95% limit of agreement around the CR value and their CIs were also calculated. 21, 22 Internal consistency reliability. The standardized coefficient a was used to estimate the internal consistency of the items of the A-IQOLS, QOLS, and other outcome measures.
Construct validity. The content validities of the QOLS and
A-IQOLS were established based on (1) the direct relevance of their root questions to the construct each is intended to measure and (2) the original research that defined the QoL dimensions to which the ratings are applied. The continued relevance of the dimensions was evaluated by considering the present importance ratings. Convergent validity was evaluated by examining the patterns and significance of the associations between the A-IQOLS and QOLS and other concurrently administered asthma outcome measures and their associations with each other. Squared correlations (R 2 ) estimate the proportion of common variance between any 2 measures. Divergent validity, the amount of unique information provided by a measure, is estimated as 1 2 R 2 , the amount of independent variance between a pair of measures, as well as variance caused by measurement error.
A significance level of .05 was used throughout. To interpret the strength of correlation coefficients, we followed the recommendation of Evans 
RESULTS

Study population
Recruitment and enrollment. Contact was attempted with 950 of the identified potentially eligible patients, 153 of whom were screened, confirmed eligible, agreed to participate, and completed in-person consent and baseline assessment. Of these, 148 (97%) completed both the baseline (test) and follow-up (retest) assessments (Strengthening the Reporting of Observational studies in Epidemiology diagram, see Fig E3 in this article's Online Repository at www.jacionline.org). One was subsequently determined to have chronic obstructive pulmonary disease and hence was ineligible, resulting in an analysis sample with 147 patients.
Baseline characteristics. Participants' mean 6 SD age was 49.1 6 12.3 years, 64.6% were female, 75.5% were white, 15.0% were black, and the remainder were Asian or another race; 11.6% were Hispanic (Table I ). The sample was largely well educated and employed/retired, with moderate-to-high income. Just over half reported adult-onset asthma, and 95.2% reported aeroallergens among their asthma triggers. Approximately three fourths (76.2%) were never smokers, and only 3.4% were current smokers. In the year before enrollment, they averaged 0. 24 Obesity has been associated with adult-asthma onset 25 and obstructive sleep apnea (OSA). 26 Because this sample has persistent and not just current asthma and obesity rates have continued to increase since 2010, the obesity and sleep apnea risk rates in this sample are not unreasonable.
Intentional oversampling of patients with more intense asthma regimens yielded a sample with 25.8% of patients at treatment step 2 or 3, 41.5% at step 4, and 32.7% at step 5 or 6 at baseline (Table I ). In the population of eligible patients with persistent asthma from which the sample was drawn, an estimated 55% were at step 2 or 3, 30% at step 4, and only 15% at step 5 or 6. Oversampling patients with more intense regimens also tended to increase heterogeneity on other associated disease parameters.
Clinical characteristics of the sample at baseline and follow-up (Table II) show that lung function averaged in the normal range, with no significant between-assessment difference. Based on ACT scores, at baseline, 54.4% of the enrolled patients had well-controlled, 22.4% had poorly controlled, and 23.1% had very poorly controlled asthma, which can be compared with estimated proportions of 63%, 17%, and 20%, respectively, among all eligible patients. At follow-up, the proportion of patients with well-controlled asthma was significantly higher (by 8.2 percentage points), with a corresponding decrease in the proportions with poorly/very poorly controlled asthma. The mean ASUI score at baseline was 0.8, indicating a relatively low level of symptoms, which is consistent with mean scores on the Marks AQLQ (mean, 13. 11 All of these asthma status measures, as well as mean A-IQOLS scores, differed significantly but by quite small amounts between baseline and follow-up.
The 4-week period preceding each assessment was examined to compare baseline and follow-up exacerbation and visit rates (Table II) . In the relatively short period of 4 weeks, visits and exacerbations were relatively infrequent, and the proportions of patients who had exacerbations and the proportion who had asthma visits did not differ significantly between baseline and follow-up (McNemar exact test: P 5 1.0 and P 5 .82, respectively).
Importance of QoL dimensions
From 63% to 94% of patients rated 15 of the 16 dimensions, including ''independence,'' as either important or very important to them (see Table E1 in this article's Online Repository at www.jacionline.org). Only ''Participation in activities relating to local and national government and public affairs'' was considered important/very important by a significantly smaller proportion of subjects (26%). All subjects had dimensions they rated as important/very important, but there was considerable individual variation in priorities. The pattern of what was typically more or less important (see Table E1 ) was generally consistent with Flanagan's earlier findings for 30-, 50-, and 70-year-olds and for men and women in the general US population. 6 This indicates that these dimensions have lasting importance to subjects despite changes in American life in the intervening 40 years. Even participation in government and civic affairs was considered important/very important by more than one third (35%) of older women.
A-IQOLS
The mean baseline (test) and follow-up (retest) A-IQOLS summary scores were 1.35 6 0.45 and 1.25 6 0.34, respectively (Table II) , indicating, on average, a relatively low perceived negative effect of asthma on patients' QoL. Subjects' summary scores ranged from 1 and 3.9. The entire rating scale range (1-5) was used in patients' ratings of impairment on the individual QoL dimensions. Ratings of 5 (extremely negative effect) were given on 7 of the 16 dimensions, and ratings of either 4 or 5 were given on 13 of the 16 dimensions. Eleven (7.5%) patients reported a negative effect on 1 or more of 9 different dimensions (material well-being, work, independence, relations with their spouse/ partner, relations with other family members, having and raising children, helping others, governmental/civic activities, and personal/spiritual development and practices) that were equal to or greater than the effect they reported on health and safety, social activities, and active recreation, which are the dominant focus of other measures commonly referred to as asthma-related QoL measures.
A-IQOLS scores differed by income level (P 5.008) but not by age, sex, race, ethnicity, level of education, or employment status (see Table E2 in this article's Online Repository at www.jacionline.org). Lower-income patients (<$75,000) believed that their asthma had a more negative effect on their QoL than those at higher income levels (A-IQOLS: mean 6 SD 5 1.53 6 0.50 vs 1.30 6 0.42). However, the association with income was not significant after controlling for ACT score (P 5 .53) because poorer asthma control was more prevalent in the lower-income patients. Patients at high risk for OSA had significantly higher A-IQOLS scores (ie, greater negative effect of asthma) than those at low OSA risk (P 5 .01). Smoking status and body mass index were not associated with A-IQOLS scores.
Baseline mean A-IQOLS scores differed significantly by level of asthma control: well controlled (1.15), poorly controlled (1.45), and very poorly controlled (1.73; P < .0001). Asthma treatment step was marginally but not significantly associated with A-IQOLS score (P 5 .07). However, the mean score for those at step 6, which is characterized by a need for routine use of multiple asthma medications (high-dose inhaled corticosteroid 1 long-acting inhaled b 2 -agonist 1 OCS 6 omalizumab), was considerably higher (1.78) than that of those at treatment steps 4 or 5 (1.34 and 1.39), which also was higher than for those at steps 2 and 3 (1.25 and 1.24). Mean A-IQOLS scores differed significantly among these 3 groups (P 5 .02).
A-IQOLS reliability. The A-IQOLS ICC was 0.56 (Table  III) . This value is similar to the ICCs of the other self-reported asthma outcome measures (see Table E3 in this article's Online Repository at www.jacionline.org). A higher ICC was observed for percent predicted FEV 1 (ICC 5 0.90), which would be J ALLERGY CLIN IMMUNOL VOLUME 141, NUMBER 3 expected for an objective but effort-dependent and labile clinical measure.
The SEM (ie, square root of the within-subject variance) is a fundamental statistic by which to evaluate the reliability of a measure (Table III) . Unlike a dimensionless index, such as ICC, the SEM is interpretable in the units of the score scale. 28 The A-IQOLS9 SEM was 60.27 scale score points. The estimated lower and upper bounds of the SEM limits of agreement, the range that contains 95% of the differences between repeated measurements on the same subject, were 20.83 and 0.63, respectively. The A-IQOLS CR was 2.77 3 SEM or 60.73 units on the effect rating scale, indicating that, with 95% probability, a within-person change in A-IQOLS score of 0.73 units or more in either direction can be considered a true/real change in the perceived negative effect of asthma. SEM values of the other asthma outcome measures and PHQ-9 are provided in Table E4 in this article's Online Repository at www.jacionline.org.
A-IQOLS internal consistency reliability. The standardized coefficient a for the A-IQOLS was high (a 5 0.91 at baseline and a 5 0.93 at follow-up) and comparable with those of the other self-reported measures on which these patients were assessed (see Table E3 ). The a coefficient, an indicator of the cross-sectional intercorrelation among the items, is commonly reported for measurement tools. However, it is not informative regarding measurement reliability, the ability of a measure to discriminate between subjects, information that is provided by the SEM (and derivative CR). The a value is most useful in item selection to achieve a reduction in the number of items, which was not relevant for the A-IQOLS or QOLS.
A-IQOLS convergent and divergent validity. With the exception of percent predicted FEV 1 , A-IQOLS scores were significantly correlated with all of the asthma status measures and depression (PHQ-9; all P < .0001) at both baseline and follow-up (Table IV) . However, in nearly all cases, the shared or common variance (R 2 ) between the A-IQOLS and other measures was less than 40%. At baseline and follow-up, ACT and A-IQOLS scores were moderately correlated (r 5 20.50 and r 5 20.53). A-IQOLS scores also were moderately correlated with ASUI (symptom) scores (r 5 20.51 and r 5 20.52) and more highly correlated with Marks AQLQ scores (r 5 0.74 and r 5 0.72) than with the ACT (asthma control), ASUI (symptom), and Juniper AQLQ scores. Even so, the common variance between Marks AQLQ and A-IQOLS scores was only about 50% and was even lower for other measures.
At baseline, neither the number of exacerbations requiring OCS use nor the number of medical visits in the preceding 4 weeks was significantly associated with the A-IQOLS score, but the follow-up correlation with exacerbations was significant (P 5 .01, Table IV ). Neither the number of exacerbations nor visits in these brief time periods accounted for a meaningful proportion of the variance in A-IQOLS scores.
Depression (PHQ-9) was significantly correlated with patients' evaluation of the negative effect of asthma on their QoL (A-IQOLS scores). However, the correlation was not strong, and the PHQ-9 and A-IQOLS scores shared only about one fifth of their variance in common.
Sensitivity of A-IQOLS to changes in asthma status. Although small, baseline to follow-up changes in asthma status measures, asthma control (ACT scores), asthma symptoms (ASUI scores), Marks and Juniper AQLQ scores, and the number of asthma medical visits were significantly correlated with changes in A-IQOLS scores in the expected directions (Table V) . Although the A-IQOLS score was significantly correlated with the number of exacerbations in the preceding 12 months (see Table E2 ), the extremely small baseline to follow-up differences in the numbers of exacerbations and asthma-related medical visits in the relatively brief (1 month) time periods preceding each assessment were not significantly associated with changes in A-IQOLS scores.
Changes in depression were significantly associated with changes in A-IQOLS scores (r 5 0.20, P 5 .01).
QOLS
Participants' mean QOLS summary scores were 3.7 6 0.8 at baseline and 3.6 6 0.7 at follow-up; on average, they believed that their needs and wants were well satisfied or very well satisfied (Table II) . The baseline to follow-up change in mean QOLS scores was borderline significant (P 5 .06). QOLS scores did not differ significantly by age, sex, race, level of education, or employment status (see Table E1 ) but were significantly associated with ethnicity (lower in Hispanics than non-Hispanics, P 5 .03) and family income (lower in those with annual family income <$75,000, P 5 .01). Smoking status and body mass index were not associated with QOLS scores. Patients at high risk for OSA had significantly lower QOLS scores than did those at low OSA risk (P 5.002). Some high-risk patients might have had OSA, especially given the high obesity rate, but some might have been reporting sleep problems largely or partially associated with asthma.
QOLS reliability. The QOLS score's within-subject ICC was 0.67 (Table III) , its SEM was 60.43, and its repeatability coefficient (CR) was 61.19 (Table III) . One can be 95% confident that a within-person QOLS score change of 1.2 units or more in either direction is a true/real change in how well the subject believes his/her needs and wants are being satisfied.
QOLS internal consistency reliability. The QOLS standardized a coefficient was 0.93 (see Table E4 ). Again, the a coefficient is not an indicator of measurement reliability.
QOLS convergent and divergent validity: correlations with health status measures. QOLs scores were not significantly correlated with percent predicted FEV 1 at either baseline or follow-up (Table IV) but were significantly correlated with the other asthma/health status measures and at follow-up only with the number of exacerbations requiring OCS use. As expected, the correlations between asthma status measures and QOLS scores and consequently their shared variances were typically lower than the corresponding correlations between these measures and A-IQOLS scores at both baseline and follow-up. Treatment step (2-6) and the number of asthma medical visits were not correlated with QOLS scores.
QOLS scores were significantly (P < .0001) but only weakly correlated 23 with A-IQOLS scores (r 5 20.39 at baseline), with only approximately 15% common variance.
The correlation between QOLS and depression (PHQ-9) scores (r 5 20.52, P < .0001) was slightly greater than that between PHQ-9 and A-IQOLS scores (r 5 0.45), but this difference was not statistically significant. 29 QOLS sensitivity to changes in asthma status. In contrast to the strong associations between changes in asthma status measures and changes in A-IQOLS scores from baseline to follow-up, changes in asthma status measures were not significantly correlated with changes in QOLS scores (Table V) . Similarly, the correlation between changes in A-IQOLS scores and changes in QOLS scores was very weak (r 5 20.15) and not statistically significant (P 5 .07), at least for the relatively small changes observed between test and retest. However, changes in depression (PHQ-9 scores) were borderline significantly correlated with changes in QOLS scores (P 5 .053).
DISCUSSION
The A-IQOLS has strong content validity; it directly queries patients about the effects of their asthma on a comprehensive set of dimensions of QoL. The continued relevance of these dimensions is supported by the present results. Its scores proved to be reliable (ie, to discriminate well between patients with differing asthma status and to have an appropriately sized SEM determined in a test-retest study) and to have strong convergent validity. Its scores and score changes were significantly correlated in the expected directions, with scores and score changes in other asthma outcome measures but not so highly correlated as to compromise its divergent/discriminant validity. The relatively low shared variances indicate that A-IQOLS scores provide unique information not provided by other asthma measures. Many of those measures that have long been included in the asthma outcome measurement toolbox continue to be useful but are not adequate proxies for a measure of the patient's perception of how his or her asthma and its treatment are affecting their QoL.
The relatively new Impact of Asthma on Quality of Life Scale CR, 2/77 3 SEM; LB, lower bound; LOA, limits of agreement; P value, P value for paired t test; SEM, OWSV; SEM (%), SEM/Mean All 3 100; t, t value for paired t test; UB, upper bound; WSV, within-subject variance from 2-way repeated-measures ANOVA. *Vaz S, Falkmer T, Passmore AE, Parsons R, Andreou P. The case for using the repeatability coefficient when calculating test-retest reliability. PLoS One 2013;8:e73990.
Information System supports development of efficient, precise, valid, responsive adult and child reported measures of health status in specific health domains (http://www.nihpromis.org/about/ missionvisiongoals) and addresses many limitations of existing generic and disease-specific health status measures. Although the Impact of Asthma on Quality of Life Scale might provide a better measure of asthmatic patients' functional status, like earlier measures, it does not directly assess the patient's perception of the effect of asthma on his or her life. Therefore, contrary to its developer's claim, it is not responsive to the central recommendation of the 2010 NIH AOW with regard to QoL measures.
Potential research uses of the A-IQOLS
In asthma research the A-IQOLS can be used to characterize study populations at baseline. A-IQOLS scores, reflecting the patients' perception of disease effect, also might have explanatory use in treatment adherence research. Importantly, a measure of patient perception of the effects of asthma and its treatment could provide an important secondary and in some cases potentially a primary outcome measure in trials of asthma therapy. In patients with moderately severe or severe asthma, in whom both the disease and its treatment can have significant negative effects, assessment of the patient's perspective might be of even greater importance and might help ensure a more complete evaluation of therapeutic benefits than is provided by physiologic, symptom, or functional status measures.
Potential research uses of the QOLS
The QOLS can be administered to any adult, regardless of health status. However, unlike other generic measures widely used in health research (eg, the 12-item Short Form Survey 32 or the EuroQol-5D 33 ), which assess symptoms, mood, and functional limitations that have a diverse cause and high prevalence in the general population (eg, pain), the QOLS measures the subject's perception of their personal QoL. The present study found that although QOLS scores are reliable and significantly correlated with A-IQOLS scores, the perceived negative effect of asthma on dimensions of a subject's QoL (A-IQOLS scores) shares only 15% variance with how well the subject believes his or her needs and wants are being satisfied (QOLS scores), and score changes in A-IQOLS and QOLS share only 2% common variance. Furthermore, in asthmatic patients QOLS scores are somewhat less strongly correlated with other asthma outcomes measures than A-IQOLS scores. This suggests that for many if not most asthmatic patients, overall QoL is less dependent on asthma than on other factors. A subject's QoL has many influences historically and at any given point in time. A health problem is just one such potential influence. It appears that a measure, such as the A-IQOLS, which asks the patient to evaluate the effect of a specific disease on his or her QoL is a more direct, sensitive, and appropriate approach than inferring effect from changes or differences in a generic measure, such as the QOLS. However, this does not mean that the QOLS has no appropriate clinical or behavioral research use. On the contrary, it is a reliable and valid measure and might be useful as a generic QoL measure for characterizing and comparing study populations, as a measure of QoL when that construct is potentially a mediator or moderator of other outcomes, and/or as a primary or secondary outcome in studies of special populations, such as those with multiple chronic diseases or diseases that are very severe, life limiting, or both.
Clinical use of the A-IQOLS and QOLS
The present study identified the minimal within-person score changes on the A-IQOLS and QOLS that represent true change. This information is critical to their potential clinical use. They provide standardized measures of patients' perceptions of their QoL and of the negative effects of asthma on their QoL by using a common conceptual framework. Both are brief, both can be completed on paper or electronically at home or in the clinic waiting room, and scoring is straightforward. These features make their clinical use more feasible. For example, patients whose asthma is not as well controlled as it might be but who believe asthma is having little negative effect (low A-IQOLS score) might be making personal choices about medication use or their activities that are satisfactory for them and might not want or warrant escalation of treatment to improve asthma control. Other patients with poorly controlled asthma might regard their asthma as having only a small negative effect because other circumstances, situations, or health conditions are having a much greater negative effect. This circumstance, if revealed to clinicians by using A-IQOLS and/or QOLS scores and ratings in conjunction with other clinical information, might prove useful in clinical management. Given the current state of knowledge, choosing the appropriate response to a patient's A-IQOLS or QOLS results would be a matter of clinician judgement. Further research is needed to determine whether the summary scores, individual dimension ratings, or both can play a useful role in informing clinical management decisions and care.
In both research and practice, a disease-specific instrument, such as the A-IQOLS, and a generic instrument, such as the QOLS, can be used separately or together. A disease-specific instrument appears most useful in patients with a single significant chronic disease or a small number of relatively distinct conditions. When rating the negative effect of a disease, it is to be expected that some patients will incorrectly attribute symptoms, functional limitations, and side effects to the disease when they actually result from another cause (eg, shortness of breath can result from asthma, obesity, or both and physical deconditioning). Conversely, patients might not recognize certain symptoms or side effects as being due to asthma or its treatment. However, such perceptions, accurate or not, can influence patients' disease management. Furthermore, this is not unique to the A-IQOLS. The same potential confusions exist in patient-reported symptoms, functional limitations, and medication side effects on asthma-related health status measures.
The QOLS can have an additional unique role to play in research and clinical practice involving patients with multiple chronic conditions, a severe or life-limiting condition, or both. In such circumstances, the goals of medical treatment are appropriately aimed at maintaining and if possible enhancing the patient's overall QoL. For that purpose, the QOLS has potential advantages over both disease-specific measures, such as the A-IQOLS, and generic measures, such as the 12-item Short Form Survey or EuroQoL. Furthermore, with disease progression can come a shift or narrowing in the areas of life that are most important to the subject, which the QOLS is uniquely able to accommodate. Further research is needed on the merits of the QOLS in patients with multiple, severe, and/or life-limiting conditions.
Limitations
The present study was intentionally broadly representative of asthmatic patients in its racial/ethnic and sex distribution and heterogeneous in level of treatment intensity and asthma severity. However, it was not designed to be representative in terms of socioeconomic status, education, or source of health care. Participants also were drawn from a single health care system, although not a closed/single insurer system; many Palo Alto Medical Foundation patients also receive care from non-Palo Alto Medical Foundation primary or specialty care providers. More importantly, the sample size is too small to determine the psychometric properties of the A-IQOLS and QOLS in specific patient subgroups, such as those with very low levels of education, particular racial or ethnic groups, or those with severe asthma. However, several other clinical trials of asthma treatment are underway that will support key subgroup analyses (to determine the generalizability of use of the instruments) and will include analyses of follow-up data from clinical trials of asthma treatment (to determine sensitivity to treatment effects, which will further inform power and sample size estimates for future clinical trials).
Finally, the present sample is too small to properly assess the incremental value of weighting subjects' responses on the A-IQOLS and/or QOLS by their personal importance ratings when computing summary scores. Typically, such weighting strategies have not proved useful, have significant computational disadvantages in scoring 28 and require collection of additional information, such as on the present Importance scale, to calculate appropriate weights. It is likely that ratings on the A-IQOLS and QOLS already take into account the importance of dimensions to the subject. However, the issue of importance weighting inevitably arises with regard to instruments of this type and will be addressed in our analysis of data from other studies now underway.
Future directions
The A-IQOLS is a model for a potential family of IQOLS measures to assess the QoL effect of other diseases, conditions, and treatments. Such measures are straightforward to create and are relevant to assessing the QoL effect of virtually any health condition or treatment. They would use the same rating scale as the A-IQOLS, but the stem question would specify whatever disease or condition was of interest. The use of a common rating scale permits direct comparison of the negative effects of different diseases and treatments on QoL and might also support cost/benefit studies. For some purposes, a bidirectional scale (both positive and negative effects) might also be used.
Conclusions
A-IQOLS is a reliable and valid measure of patients' perception of the effect of asthma on their QoL, providing unique information not provided by other asthma self-report measures that assess patient's symptoms and functional status. Further study is needed to understand the performance of this measure in particular patient subgroups, its sensitivity to the effects of different therapeutic interventions, and its value in clinical care. The success of the IQOLS approach in asthmatic patients suggests that this type of measure might be useful in patients with other diseases as well. The Flanagan QOLS is a reliable and valid measure of patients' perception of whether their needs and wants are being satisfied and yields a score that represents their perceived QoL. Although less sensitive than the A-IQOLS to change in disease status, it has potential value in characterizing study populations and as an outcome measure in research involving persons with severe, multiple, or life-limiting conditions. Both the A-IQOLS and QOLS appear to be useful in clinical research and potentially useful in clinical care.
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